Pfizer/BioNTech begin Omicron vaccine trial

Posted 25 January, 2022

Pfizer and its German partner BioNTech are starting a trial to evaluate an Omicron-based Covid-19 vaccine in healthy adults aged 18 to 55. “While current research and real-world data show that boosters continue to provide a high level of protection against serious illness and hospitalization with Omicron, we recognize the need to be prepared in the event that this protection fails. would weaken over time and potentially help cope with Omicron and newer variants in the future,” Pfizer said.

The study will include up to 1,420 participants divided into three cohorts: one will include people who received two doses of the current Pfizer/BioNTech Covid vaccine 90 to 180 days before enrollment, this group receiving one or two doses of the Omicron vaccine; another will include people who have received three doses of the current vaccine and will receive one dose of the current vaccine or the Omicron vaccine; and a third group of "vaccine naïve" people, who will receive three doses of the Omicron vaccine.

Previous story

25 January, 2022 14:41

← Nigeria backs out of fuel subsidy removal

The Nigerian government has announced that it is once again abandoning the abolition of fuel subsidies, a measure extremely popular in Africa's most populous country, a year before the presidential election.

Nigeria backs out of fuel subsidy removal

Next story

24 January, 2022 16:08

Turkish Finance Ministry expects inflation at 40% →

Turkey's Treasury and Finance Minister Nureddin Nebati said Turkey's inflation in February will be high but will fall by 14 percentage points by the end of the year, while the minister expects domestic inflation to reach 40% per annum for several months.


Turkish Finance Ministry expects inflation at 40%
Write a comment
Prove you’re not a bot + 20 = 38